RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-2.86%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.33B
AUM Growth
+$4.33B
(-9%)
Cap. Flow
+$22M
Cap. Flow
% of AUM
0.51%
Top 10 Holdings %
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
81
Reduced
15
Closed
21
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$86.2M |
| 2 |
Baxter International
BAX
|
$24.4M |
| 3 |
Xilio Therapeutics
XLO
|
$19.1M |
| 4 |
Aura Biosciences
AURA
|
$17.1M |
| 5 |
Compass Therapeutics
CMPX
|
$16.9M |
Top Sells
| 1 |
Teleflex
TFX
|
$49M |
| 2 |
ALLK
Allakos
ALLK
|
$32.4M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$26.3M |
| 4 |
Bolt Biotherapeutics
BOLT
|
$20.9M |
| 5 |
OSH
Oak Street Health, Inc.
OSH
|
$18.8M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Consumer Staples | 1.28% |
| 3 | Industrials | 0.73% |
| 4 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Agilon Health
AGL
$530M
| $202M | 4.68% | 7,495,000 +420,000 | +6% | +$11.3M |
|
2
Humana
HUM
$36.5B
| $162M | 3.74% | 349,000 +7,000 | +2% | +$3.25M |
|
3
Align Technology
ALGN
$10.3B
| $131M | 3.04% | 200,000 | – | – |
|
|
4
Intuitive Surgical
ISRG
$170B
| $129M | 2.99% | 360,000 +240,000 | +200% | +$86.2M |
|
5
Insulet
PODD
$23.9B
| $123M | 2.85% | 463,750 +26,184 | +6% | +$6.97M |
|
6
UnitedHealth
UNH
$281B
| $121M | 2.78% | 240,000 | – | – |
|
7
Idexx Laboratories
IDXX
$51.8B
| $119M | 2.74% | 180,000 | – | – |
|
8
HCA Healthcare
HCA
$94.5B
| $116M | 2.67% | 450,000 | – | – |
|
9
argenx
ARGX
$43.6B
| $110M | 2.55% | 315,000 | – | – |
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $94.1M | 2.17% | 1,105,000 +53,500 | +5% | +$4.56M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $92.1M | 2.13% | 859,755 +10,096 | +1% | +$1.08M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $87M | 2.01% | 2,646,625 +90,446 | +4% | +$2.97M |
|
13
Immunocore
IMCR
$1.62B
| $84.6M | 1.96% | 2,471,555 +26,400 | +1% | +$904K |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $80.4M | 1.86% | 746,000 +44,000 | +6% | +$4.74M |
|
15
Edwards Lifesciences
EW
$47.8B
| $75.4M | 1.74% | 582,000 | – | – |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $74.3M | 1.72% | 883,921 +82,812 | +10% | +$6.96M |
|
17
Zai Lab
ZLAB
$3.68B
| $74.2M | 1.71% | 1,180,700 +102,950 | +10% | +$6.47M |
|
|
18
Baxter International
BAX
$12.7B
| $63M | 1.46% | 733,803 +283,803 | +63% | +$24.4M |
|
19
Novavax
NVAX
$1.21B
| $60.8M | 1.4% | 425,000 -30,000 | -7% | -$4.29M |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $60.2M | 1.39% | 410,415 +56,901 | +16% | +$8.35M |
|
21
Pacira BioSciences
PCRX
$1.2B
| $60.2M | 1.39% | 1,000,000 | – | – |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $57.9M | 1.34% | 714,000 +78,300 | +12% | +$6.35M |
|
23
Evolent Health
EVH
$1.12B
| $56.4M | 1.3% | 2,038,000 +163,000 | +9% | +$4.51M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $56.4M | 1.3% | 332,500 +21,500 | +7% | +$3.65M |
|
25
Aclaris Therapeutics
ACRS
$209M
| $56.1M | 1.3% | 3,861,347 +58,115 | +2% | +$845K |
|